BridgeBio Pharma (BBIO) Profit After Tax (2018 - 2026)

BridgeBio Pharma has disclosed Profit After Tax across 9 years of filings, most recently posting -$166.6 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at -$166.6 million, up 1.8% year-over-year; the trailing twelve-month figure through Mar 2026 was -$729.9 million (down 7.84% YoY), and the FY2025 annual result was -$732.9 million, down 34.89% from the prior year.
• Profit After Tax came in at -$166.6 million for Q1 2026 at BridgeBio Pharma, up from -$194.6 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$2.6 million in Q2 2022 to a low of -$267.4 million in Q4 2024.
• The 5-year median for Profit After Tax is -$166.6 million (2026), against an average of -$151.8 million.
• Across the five-year window, Profit After Tax surged 97.49% in 2022 and tumbled 6179.91% in 2023, its largest moves.
• BridgeBio Pharma's Profit After Tax stood at -$140.6 million in 2022, then dropped by 21.17% to -$170.3 million in 2023, then slumped by 56.98% to -$267.4 million in 2024, then rose by 27.21% to -$194.6 million in 2025, then rose by 14.43% to -$166.6 million in 2026.
• The last three Profit After Tax figures came in at -$166.6 million (Q1 2026), -$194.6 million (Q4 2025), and -$184.9 million (Q3 2025), per Business Quant data.